Tuesday, April 23, 2013
Senesco Technologies Inc., of Bridgewater, N.J., completed the second cohort of its Phase Ib/IIa trial of SNS01-T. Two multiple myeloma patients and one diffuse large B-cell lymphoma patient have completed the study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.